<?xml version="1.0" encoding="UTF-8"?>
<p>Partial NMDA-receptor antagonist has been used as a therapeutic option to treat PD patients with cognitive defects in several placebo-controlled trails [
 <xref rid="B101" ref-type="bibr">101</xref>â€“
 <xref rid="B104" ref-type="bibr">104</xref>]. However, the results of studies were not consistent or notable; only one trial showed statistical differences in the improvement of global cognition [
 <xref rid="B102" ref-type="bibr">102</xref>], whereas most of trials suggested no pharmacological effects of partial NMDA-receptor antagonist on neuropsychiatric symptoms or improvement of daily life [
 <xref rid="B105" ref-type="bibr">105</xref>].
</p>
